EUVIMEDEUVIMED entdecken
Crossref

Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device

Sarah Shahub, Ruchita Mahesh Kumar, Kai-Chun Lin, Ivneet Banga, Natalie K Choi, Nicole M Garcia, Sriram Muthukumar, David T Rubin, Shalini Prasad iD

Inflammatory Bowel Diseases · 03.03.2025 · 31 (3) · 647-654

DOI: 10.1093/ibd/izae054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.03.2024. Verfasst von Sarah Shahub und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Texas at Dallas, Dallas, TX, USA. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, C-Reactive Protein, Interleukin-6, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Crohn's and Colitis Foundation, Crohn’s and Colitis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Wearable sensor devices represent a noninvasive technology to continuously track biomarkers linked to inflammatory bowel disease (IBD). We assessed the inflammatory markers associated with IBD in human perspiration.

Methods

Participants with IBD were monitored for 40 to 130 minutes with a proprietary wearable sensor device used to measure C-reactive protein, interleukin-6, and calprotectin. Sensor response using electrochemical impedance spectroscopy and serum samples were measured on the same day. The Mann-Whitney test was used to analyze the relationship between active and remission IBD in serum and perspiration, classified according to endoscopic reports and serum biomarker levels. Asynchronously collected fecal calprotectin from a subset of the population was similarly analyzed.

Results

A total of 33 subjects were enrolled. Expression of calprotectin was significantly elevated in the active cohort compared with the remission cohort in perspiration (P < .05; median = 906.69 ng/mL; active 95% confidence interval [CI], 466.0-1833 ng/mL; remission 95% CI, 328.4-950.8 ng/mL), serum (median = 1860.82 ng/mL; active 95% CI, 1705-2985 ng/mL; remission 95% CI, 870.2-1786 ng/mL), and stool (P < .05; median = 126.74 µg/g; active 95% CI, 77.08-347.1 µg/g; remission 95% CI, 5.038-190.4 µg/g). Expression of CRP in perspiration and serum was comparable between the active and remission cohorts (perspiration: P > .05; median = 970.83 pg/mL; active 95% CI, 908.7-992 pg/mL; remission 95% CI, 903.3-991.9 pg/mL; serum: median = 2.34 µg/mL; active 95% CI, 1.267-4.492 µg/mL; remission 95% CI, 1.648-4.287 µg/mL). Expression of interleukin-6 in perspiration was nonsignificant in the active cohort compared with the remission cohort and was significantly elevated in serum (perspiration: P < .05; median = 2.13 pg/mL; active 95% CI, 2.124-2.44 pg/mL; remission 95% CI, 1.661-2.451 pg/mL; serum: median = 1.15 pg/mL; active 95% CI, 1.549-3.964 pg/mL; remission 95% CI, 0.4301-1.257 pg/mL). Analysis of the linear relationship between perspiration and serum calprotectin (R2 = 0.7195), C-reactive protein (R2 = 0.615), and interleukin-6 (R2 = 0.5411) demonstrated a strong to moderate relationship across mediums.

Conclusions

We demonstrate the clinical utility of perspiration as a noninvasive medium for continuous measurement of inflammatory markers in IBD and find that the measures correlate with serum and stool markers across a range of disease activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexC-Reactive ProteinInterleukin-6Inflammatory Bowel DiseasesWearable Electronic DevicesHumansMaleFemaleBiomarkersAdultMiddle AgedFecesYoung Adult

Stichwörter der Autor:innen

C-reactive proteinCrohn’s diseasecalprotectininterleukin-6perspirationulcerative colitis

Substanzen

Leukocyte L1 Antigen ComplexC-Reactive ProteinInterleukin-6BiomarkersIL6 protein, human

Autor:innen und Institutionen

  • Department of Bioengineering, University of Texas at Dallas, Dallas, TX, USA.
  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
  • EnLiSense LLC, Allen, TX, United States.

ORCID-Profile: Shalini Prasad

Förderung

  • Crohn's and Colitis Foundation
  • Crohn’s and Colitis Foundation

Zitieren

APA

Shahub, S., Kumar, R. M., Lin, K. C., Banga, I., Choi, N. K., Garcia, N. M., Muthukumar, S., Rubin, D. T., & Prasad, S. (2025). Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflammatory Bowel Diseases, 31(3), 647-654. https://doi.org/10.1093/ibd/izae054

Vancouver

Shahub S, Kumar RM, Lin KC, Banga I, Choi NK, Garcia NM, et al. Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflammatory Bowel Diseases. 2025;31(3):647-654. doi:10.1093/ibd/izae054

BibTeX
@article{Shahub2025,
  author = {Shahub, Sarah and Kumar, Ruchita Mahesh and Lin, Kai-Chun and Banga, Ivneet and Choi, Natalie K and Garcia, Nicole M and Muthukumar, Sriram and Rubin, David T and Prasad, Shalini},
  title = {Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {647--654},
  doi = {10.1093/ibd/izae054}
}
Kostenlos starten →